Qyuns Therapeutics (HKG:2509) has received a $5 million milestone payment from partner Caldera Therapeutics after its bispecific antibody QX030N/CLD-423 obtained approval from Australia's Human Research Ethics Committee for a Phase 1 clinical trial, according to a Tuesday Hong Kong bourse filing.
Shares of the biotech firm rose nearly 4% in Wednesday morning trade.
The study, set to begin in early 2026, will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics across single and multiple IV and subcutaneous dosing in healthy adults, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments